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1. Introduction 
In 1977, Dunnill et al. from Oxford at first reported that 14 of 30 dialysis patients with end 
stage renal disease (ESRD) examined at autopsy had acquired cystic disease of the kidney 
(ACDK) and that six of these 14 patients had renal cell carcinoma (RCC), including one with 
distant RCC metastatsis.1  It is now well established that patients with ESRD are more prone 
to RCCs with an incidence of approximately 3 to 5 %.2-5 These studies may misrepresent the 
true incidence RCC because they primarily relay upon screening radiology, particularly 
ultrasonography (US), for detection. Better estimate was provided by a single-center study 
in which most renal transplant patients undergo ipsilateral native nephrectomy at surgery. 
Based upon strict pathologic criteria reported by Denton et al., prevalence of ACDK, renal 
adenoma and RCC and oncocytoma were found in 33%, 14%, 4.2% and 0.6% of 260 
patients6, which may be lower than the true incidence given that only one kidney was 
removed.  
Chen et al. found higher incidence of RCCs vs. the general population, with a standardized 
incidence ratio of RCC in dialysis patients of 24.1 (p <.01)7. Ishikawa et al. were able to 
demonstrate that time spent on haemodialysis was the most important risk factor for ACDK 
and also for the development of RCC. This important observation did highlight the key 
features of ACDK developing on haemodialysis and apparently increasing the likelihood of 
RCC2,8,9. Hughson’s work suggested that during this time there was a progression of cystic 
lesions from simple to complex or hyperplastic cysts and on to renal tumor formation10. 
A recent nation-wide survey in Japan revealed a 15-fold increase in the number of dialysis 
patients with RCC in the last 2 decades8. Reasons for this rapid increase can be postulated as 
follows: the increasing number of dialysis patients: the increasing duration of dialysis in 
these patients: and the prevalence of tumor screening in dialysis patients by imaging 
studies. The prevalence of ACDK in the haemodialysis population in Japan appears to be 
higher than that in the USA or Europe and patient survival on dialysis in Japan is 
significantly longer. These are probably because of different patterns of primary renal 
disease and reduced cardiovascular comorbidity compared with Western populations11. The 
presence of RCCs also appears to vary within different populations. Kojima’s study of 2624 
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dialysis patients found that 81.8% of their patients had ACDK on a median dialysis time of 
11 years with 44 patients (1.68%) of RCCs. This compares with studies from the USA 
suggesting approximately one-fifth of the 30% or so patients with ACDK will have RCC, 
therefore close to 6% of the overall dialysis population5. This 3- to 4-fold difference in the 
risk of RCC in ACDK between Japan and the USA may be real or may be a consequence of 
differences in study populations or of methods used to screen patients.  
Dialysis patients with RCC are one of the representative groups of patients with 
considerable surgical risks. According to the American Society of Anesthesiologists (ASA) 
classification (http://www.asahq.org/clinical/physicalstatus.htm)12, surgical risk of 
patients with chronic renal failure (CRF) is assigned to at least physical status (PS) 3. 
Dialysis patients often have multiple complications such as respiratory or cardiac problems 
in addition to CRF. Since the number of RCCs in dialysis patients associated with high 
surgical risk is also expected to increase, a safe and less invasive radical nephrectomy is 
warranted.  
Laparoscopic radical nephrectomy (LRN) has been used for the management of renal mass 
in ESRD patients and showed acceptable surgical outcomes13-16. Since 1998, we have 
developed gasless single-port retroperitoneal RN for RCC designated minimum incision 
endoscopic surgery, MIES17-19. This operation is completed via a single port that narrowly 
permits extraction of the kidney with perinephric fat, without CO2 gas insufflation, and 
without injury to the peritoneum17-19. This operation was certified as advanced surgery by 
the Japanese government in 2006, and was covered by the Japanese universal insurance 
system from April, 200818,19. MIES RN has been shown to be a suitable treatment modality 
for an expanding spectrum of high risk patients such as RCC in ACDK patients. We already 
reported the experience of this operation for initial 8 ESRD patients20 and 7 bilateral cases in 
ESRD patients21. 
In this context, we will review the recent data about renal neoplasm in ESRD patients 
including our published papers and recent experiences. 
2. Minimum incision endoscopic surgery (MIES) for dialysis patients 
2.1 Patients and sources 
We reviewed our single-center consecutive cases undergoing MIES RN for RCC in ESRD 
patients between 1998 and 2009. This database contains information regarding a large 
number of variables relating to patient characteristics and their surgical procedures. 
Evaluable parameters included age, gender, side of surgery, duration of dialysis, symptoms, 
radiological findings, body mass index (BMI) calculated by height and weight, physical 
status according to the American Society of Anesthesiologists (ASA) scoring system12. Time 
to feeding and walking after the surgery were also recorded.  
2.2 Surgical treatment 
The surgical technique of MIES RN, was previously demonstrated17-19. Briefly, the minimum 
incision, around 4 to 6 cm depending on the size of the specimen that narrowly permits 
extraction of the kidney covered with perinephric fat is made obliquely forward following 
the line of the 12th rib (fig.1). Muscles are separated without cutting and a small space is 
made under the laterocoronal fascia to allow positioning of a Wound Retractor. After a 
single port was made, the working space is created by dissecting along the anatomical 
planes extraperitoneally with long retractors and spatulas under the guidance of both 
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endoscope and direct vision. The peritoneum is kept intact during the operation. When 
isolated, the kidney with perinphric fat is put into the pouch (flexible catcher) in the surgical 
field to prevent rupture of the specimen and extracted through the incision. All procedures 
are carried out without trocar ports, without gas insufflation and without the insertion of 
the hands of operators into the operative field. For reducing the bacterial contamination, 
operative field and subcutaneous space were rinsed with approximately 2000ml and 100ml 
sterile saline, respectively, before skin closure. Skin is closed by subcuticular suture using 
polydioxanone, followed by Dermabond. There were no additional dressing or treatment 
applied postoperatively. Only two inexpensive devices, the wound retractor and the 
specimen catcher, are disposable in this operation which results in low equipment cost. 
The most dialysis patients subject haemodialysis the day before surgery, as well as one day 
postoperatively, to maintain their routine dialysis schedule. Serum electrolytes were closely 
monitored, both preoperatively and postoperatively. Patients were discharged home when 
they met standard discharge criteria and were seen at 1 month, 6 months, 12 months, and at 
appropriate intervals (relating to their cancer diagnosis and other urological issues) 
thereafter, in the out-patients clinic for follow-up.  
 
 
 
 
 
 
Fig. 1. Resected specimen of ACDK-RCC covered by flexible catcher and 5cm single-port. 
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2.3 Outcomes of MIES- RN for dialysis patients 
We conducted 57 MIES RN for 50 ESRD patients including 7 bilateral RCC cases. For 
bilateral RCC cases, we have performed sequential operation. When bilateral RCCs are 
suspected concomitantly, we performed the first RN on the kidney that harbors the larger 
tumor. After confirming the diagnosis pathologically, the second RN is performed 
sequentially21.   
MIES RN was successfully completed in all 57 cases with a mean (SD; range) age at RN of 
58.6 (10.2; 35-80) years. The mean (SD) operative time was 170 (47) minute with mean (SD) 
estimated blood loss of 218 (231) cc. The mean (SD; range) length of the extraction incision 
was 6.1(1.2; 4-9) cm and all kidney specimens with mean (SD) weight of 358 (303) gram were 
removed intact via single-port. 1 patient required blood transfusion (1.8%). Other 
complications were not found during operation. The average (SD; range) days to oral 
feeding and walking were postoperative 1.4 (0.5; 1-3) and 1.3 (0.6; 1-3) days, respectively. 
Circulatory and respiratory problems did not occur after operation.  
Several studies have been performed involving patients with ESRD undergoing 
laparoscopic RN for RCCs (table.1). 
 
Authors yr n operation 
Trans-
peritoneal 
(Renal 
units) 
Retro-
peritoneal 
(Renal units) 
Mean 
EBL (ml)
Mean 
operative 
time (min) 
Others 
Current 
Study 
 57
MIES (gasless 
single-port)17-19,22
0 57 218 170  
Bird et al16 2009 16 laparoscopic 16 0 153 
−
 
Reza 
Ghasemian 
et al15 
2005 10 laparoscopic 
20 
(bilateral) 
0 164 
390 
(bilateral) 
 
Gulati et 
al14 
2003 5 laparoscopic 4 2 120 294 
Open 
conversion 
in one case 
Iwamura et 
al13 
2001 6 laparoscopic 0 6 58 162  
Table 1. Summary of minimally invasive radical nephrectomy for RCC patients with ESRD 
3. Pathological findings of RCC in dialysis patients 
3.1 Characteristics of dialysis patients 
We evaluated 57 cases consisting of 43 cases in 38 men and 14 cases in 12 women. Seven 
bilateral RCC (five men and two women) cases were found. The median (range) duration of 
dialysis was 12 years (0-27). ACDK was found in 35 patients (70%). On the basis of the 
duration of dialysis, all cases were classified into four groups: group A, 0-3 years (n=11); 
group B, 4-10 years (n=15); group C, 11-20 years (n=21) and group D, 21-30 years (n=10).The 
effects of duration of dialysis on the ACDK state in fig. 2. With increasing duration of 
dialysis, % proportion of ACDK kidney increased (p< 0.0001). Also, univariate and 
multivariate analysis incorporating into age, gender and duration of dialysis indicated that 
longer duration of dialysis was an independent predictor of development of ACDK (p< 
0.0001).  
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Fig. 2. Transition of proportion of acquired cystic disease of kidney (ACDK) in each group. 
As the duration of hemodialysis becomes longer, the proportion of ACDK increases (p< 
0.0001). 
3.2 Macroscopic and microscopic findings 
There was no correlation between the average size of the tumors and the duration of 
hemodialysis in all cases. Only in ACDK-RCCs, maximal tumor diameter tend to increase 
with longer duration of haemodialysis but did not reach to a significant difference 
(p=0.09).    
The main tumors and its associated foci (previously categorized according to the WHO 1998 
classification system) were re-evaluated histopathologically according to the WHO 2004 
classification of renal neoplasms and the 2009 TNM staging classification system 
(http://www.uicc.org/tnm). Although there is no consensus on the terminology of these 
special tumors, we used the term of Tickoo et al23. As a result, the current 57 cases were 
classified into 32 ACDK-RCCs corresponding to unclassified carcinoma in the current WHO 
classification, 22 clear cell RCCs and 3 papillary RCCs.  
As regards the histological type of the tumors, ACDK-RCCs were more frequent (32/57 
lesions, 56.1 %) than clear cell RCCs (22/57 lesions, 38.6%) or papillary RCCs (3/57 lesions, 
5.3%). The ratio of ACDK-RCCs in the haemodialysis-related RCCs of each group increased 
concomitantly with the increase in the duration of haemodialysis; group A, 0/11 (0%); 
group B, 7/15 (46.7%); group C, 17/21 (81.0%); and group D, 8/10 (80%). Multivariate 
analysis incorporating into age, gender and duration of dialysis indicated that longer 
duration of dialysis was an independent predictor of development of ACDK-RCCs (p< 
0.0001). Male gender also had a tendency to predict ACDK-RCCs but did not reach to a 
significant difference (p=0.08).  
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ACDK-RCCs had papillary, tubular or tubulocystic structures covered by neoplastic cells 
with large round or oval to irregularly shaped nuclei with or without prominent nucleoli 
and eosinophilic granular or focally relatively clear cytoplasms (Figure 3). All of them 
appeared to develop in close relation to the cystic regions and occasionally showed 
intratumoral calcium oxalate crystals deposition. Because the above-stated histopathological 
architecture of ACDK-RCCs was usually absent in conventional RCC, these ACDK-RCCs 
appeared to be difficult to classify into the known subtypes of RCC.  
 
 
Fig. 3. Acquired cystic disease-associated renal cell carcinoma (ACDK-RCC), the most 
common tumor identified in ESRD, but only in cases with ACDK. A, This tumor shows a 
variegated architecture, including papillary, solid, and clear cell like areas. B, The tumor 
reveals papillary or tubular growth pattern of neoplastic cells with eosinophilic cytoplasms 
and round nuclei. C, Clear-cell RCC-like areas were focally present. D, ACDK-RCC with 
sarcomatoid changes were focally present.  
3.3 Comparison of ACDK RCCs and non-ACDK RCCs  
The mean duration of haemodyalysis was significantly longer in the ACDK-RCC cases (15.9 
years) than in the non-ACDK-RCC (clear cell RCC and papillary RCC) cases (6.8 years) (p 
<.0001).There were no significant differences of age, laterality, tumor size, pathological T 
between two groups. % of male patients tend to be higher in the ACDK-RCC group (85%) 
than in in the non-ACDK-RCC (63%) (p=0.07). Two cases of ACDK-RCCs revealed 
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aggressive behavior, i.e. death from cancer. Those ACDK-RCCs with aggressive behavior 
tend to be detected in patients with longer duration of haemodialysis; both cases belonged 
to group D.  
4. Discussion 
4.1 Development of ACDK 
During the past 20 years, ACDK has become more prevalent as patients with ESRD live 
longer, undergo more sensitive diagnostic imaging of the kidneys, and are less likely to 
undergo pretreatment bilateral nephrectomy. ACDK has been defined as macroscopic cystic 
structures compromising at least 25% of the renal parenchyma or greater than 3 cysts per 
kidney in a patient in renal failure who was not known to have cysts prior to the onset of 
renal failure and in whom there is no family history or other evidence of an inherited cystic 
disease1. Of patients on dialysis for less than 3 years 10% to have ACDK, 40% to 60% on 
dialysis for 3 years have ACDK and more than 90% have ACDK after 5 years on dialysis24. 
The current study also demonstrated that duration of dialysis was closely related with 
development of ACDK. After three years, proportion of ACDK dramatically increased. 
Cysts may be found in some patients with renal impairment prior to the initiation of dialysis 
treatment25. Ishikawa et al. reported that when male patients with ESRD were introduced to 
hemodialysis, the kidney volume was minimized because of the loss of hypertrophied 
nephrons 3.6 years after the start of haemodyialysis, and thereafter, the kidney enlarged due 
to the development of ACDK. The maximum kidney volume was obtained at 21.1 years 
after the start of hemodialysis9,26. ACDK may occur less frequently in those who are on 
peritoneal dialysis and may regress after transplantation27.  
4.2 Incidence of RCC in ESRD patients 
the published incidence of RCCs in patients depends on the investigation method 
(radiologic, surgical, or autopsy). It is well established that patients with ESRD are more 
prone to kidney neoplasms with an incidence of 4.2% to 5.8%28. Those patients with ESRD 
who also have ACDK are even more prone to the development of carcinoma, with an 
incidence of 7%23. In United States, approximately 20% of those with ACDK will have RCC5. 
In Japan, Terasawa et al.4, Satoh et al.29 and Kojima et al.11 reported 2.6% (41/ 1603), 0.61% 
(38/6201) and 1.68% (44/2624) of RCC in their patients on hemodialysis,respectively. Such 
an incidence of RCC appears significantly high, compared with that reported in the general 
Japanese population where RCC develops in 7.1 of 100000 men and 3.1 of 100000 women, 
and age-standardized incidence rates per 100 000 population for men and women were 4.9 
and 1.8, respectively30. In Japan, longer dialysis patients have been dramatically increasing 
probably because of low cardiovascular comorbidity and low incidence of renal 
transplantation, leading to development of ACDK and RCC.  
4.3 Diagnosis of RCC in ESRD patients 
Diagnosis of RCC in dialysis patients may sometimes be difficult because the majority of the 
RCCs arise from multiple cysts of ACDK and theses RCCs are sometimes not enhanced well 
in computed tomography. Schwarz et al.5 recommended a screening and management 
protocol in transplant recipients, incorporating the the Bosniak Renal Cyst Classification 
System31.Complex cystic lesions were defined as those with irregularly thickened cyst walls, 
hyperdense or nonhomogenic cyst content and/or pronounced intrarenal calcifications, 
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and/or positive enhancement after intravenous application of contrast media (Bosniak 
category IIF to III). Ultrasound was followed by computed tomography (CT) scan or 
magnetic resonance imaging (MRI) when a moderately complex cystic lesion of the kidney 
was found (Bosniak category IIF) or in case of suspicion of renal cell carcinoma (category III 
or IV). Importantly, they recommended the nephrectomy in the case of progressive lesions, 
even if not reaching category III or IV. This is true especially for cystic lesions of category 
IIF. Fundamentally, we also underwent follow up with ACDK for screening of RCC 
according to the Bosniak Renal Cyst Classification System. Recently, we introduced 
diffusion-weighted MRI for detection of ACDK-RCC, which is now under investigation.  
 
 
Fig. 4. Multidetector computed tomography for ACDK-RCC. Enhanced mass was found in 
left kidney (Bosniak category III).  
Important problem is, how frequent is multifocality and bilaterality of tumors in ESRD. In 
the current study, bilateral RCCs were pathologically confirmed in 14% (7/50) of the 
dialyzed patients. This figure, consistent with previous reports11,23, is considerably higher 
than in sporadic RCC in non-dialyzed patients which is reported as being approximately 
4%32. Ghasemian et al. reported that because of the increased risk of developing RCC in the 
contralateral kidney, they performed bilateral laparoscopic RN in 10 patients. Of them, 2 
patients had bilateral RCC15. Kojima et al. reported that satellite RCC nodules were detected 
in 29.5% of their patients with ACDK, whereas bilateral tumors were present 11.4%. When 
bilateral RCCs are suspected concomitantly, we performed the first RN on the kidney that 
harbors the larger tumor. After confirming the diagnosis pathologically, the second RN is 
performed sequentially21. We think that prophylactic nephrectomy should be avoided and 
followed up by imaging even after unilateral nephrectomy.   
4.4 Minimum incision endoscopic surgery, MIES for RCC ; gasless single-port 
retroperitoneal RN 
The perioperative management of ESRD patients is often complex. These patients are at 
increased risk of postoperative complications secondary to bleeding diathesis, 
hemodynamic instability, and immunosuppression. They also have higher risk during 
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anesthesia due to the multiple comorbidities, which include concomitant cardiovascular and 
respiratory issues. Preparation of the dialysis patient before the operation should include 
early withdrawal of drugs that affect platelet function, such as aspirin and non-steroidal 
anti-inflammatory drugs33. Preoperative optimization of platelet function and hematologic 
status may reduce intraoperative bleeding and the need for blood transfusion. Fornara et al. 
noted an increased transfusion rate in 19-dialysis-dependent patients undergoing 
laparoscopic nephrectomy (32%) compared with a similar group without renal failure (0%). 
They attributed this difference, not to increased blood loss or bleeding diatheses, but to a 
lower initial serum hemoglobin34. In our series, only one (1.8%) patients received 
transfusion. Recently, there were few patients with severe anemia even in ESRD patients by 
utilizing erythropoietin.  Serum electrolytes should be closely monitored, both 
preoperatively and postoperatively. In addition, patients should not receive excessive 
amounts of intravenous fluids. Early dialysis may be necessary if serum electrolyte 
abnormalities or volume overload is present postoperatively.  
Laparoscopic radical nephrectomy (LRN) for ESRD patients may offer an acceptable 
treatment modality with less invasiveness when compared with open RN35,36. Despite the 
several benefits of laparoscopic surgery such as reduced post-operative pain, shorter 
hospital stay, more rapid return to daily activities and so on, intra-abdominal CO2 
insufflation has various potential risks that may affect the cardiovascular and respiratory 
system. The pressure effects of pneumoperitoneum decrease cardiac output and stroke 
volume. The pressure effects also decrease respiratory compliance and increase airway 
pressure, with possible barotraumas, pneumothorax, and increased intracranial pressure. 
Gulati et al. reported a case of unexplained hypercarbia and hypotension developed during 
attempted retroperitoneal LRN requiring termination of the operation14. If CO2 retention is 
problematic, the intra-abdominal pressure should be reduced and minute ventilation 
increased. Some have proposed performing laparoscopic procedures using abdominal wall 
retraction, rather than insufflation, in high-risk patients37,38. Bird et al. suggested that 
insufflation pressure for ESRD patients should be lower as compared with that for that for 
non-ESRD patients16.  
In patients with prior peritoneal dialysis, significant intra-abdominal adhesions can be 
encountered. Moreover, transperitoneal surgery itself could result in intraperitoneal 
adhesion which is not desirable for future peritoneal dialysis for ESRD patients or other 
abdominal operation. Retroperitoneal LRN approach has been shown to be a safe treatment 
modality for renal masses in ESRD patients13. 
Venous CO2 embolism is a recognized risk during laparoscopic procedures. Its clinical 
presentation ranges from asymptomatic to neurogenic injury, cardiovascular collapse or 
even death depending on the rate and volume of gas entrapment and patient condition. 
Venous CO2 embolism of laparoscopy occurs in 15 per 100,000 cases per year39,40. Incidences 
of subclinical embolism during various laparoscopic procedures have been reported to 
occur in as much as 6% of nephrectomy cases41 and 17.1% total prostatectomy cases42 when 
transesophageal echocardiography (TEE) was used for monitoring. Serious clinical events 
related with venous CO2 embolism have been reported during laparoscopic 
nephrectomy43,44 but not during laparoscopic radical prostatectomy. Gas embolism occurred 
during 2 distinct periods; first, during peritoneal insufflation, and second, during venous 
complex dissection45. Early signs of gas embolism include a rapid drop in end-tidal CO2 and 
PaO2 and an increase in PaCO2 and can be followed by hypotension, hypoxia, cyanosis, 
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arrhythmia, or cardiac arrest. Elderly or high-risk patients with limited cardiopulmonary 
reserve might not be able to tolerate these situations.  
Based on these above findings, non-use of CO2 gas and retroperitoneal approach are 
considered to be key points for lesser invasive surgery for ESRD patients with renal tumors.   
In this study, we demonstrated that MIES RN is a feasible treatment for RCC in ESRD 
patients requiring dialysis. Bleeding and operation time were comparable to LRN, as 
shown in Table.2. We already reported that this operation has minimal invasiveness 
similar to that of LRN17 and an oncological outcome similar to that of open surgery22. 
Operative time and blood loss are similar to those in open surgery and complications 
including blood transfusion are very rare17. Postoperative data, days to oral feeding and 
days to walking are reported to be equal or sooner compared with LRN17 and surgical site 
infection is extreamly rare despite the lack of use of prophylactic antibacterial agents46. 
These findings hold true even in ESRD patients.   We stress that this operation has the 
following advantages over LRN especially for high risk group including ESRD: 1) this 
operation does not impose circulatory and respiratory stress on ESRD patients and avoids 
risks of venous embolism, air embolism, and venous thrombosis, which are actually rare, 
but can be lethal when they occur because of non-use of CO2 during operation, 2) this 
operation leaves peritoneal cavity intact, leading no concern about intra-peritoneal 
adhesion after nephrectomy which is not desirable for possible future peritoneal dialysis 
and other operations, and 3) this operation can be performed even in patients with a 
history of intra-peritoneal surgery. In Japan, patients with ACDK-RCC have been 
increasing now. The cost of disposable instruments in this operation is much lower than 
that in LRN47. Based on these advantages, gasless single-port retroperitoneal RN seems to 
be ideal minimally invasive surgery for ESRD patients.   
4.5 Pathology 
In the present study, ACDK development in patients with ESRD/dialysis is associated with 
a higher risk of RCC and that the duration of dialysis is the main determinant of this risk. 
Papillary RCC has been previously reported to be the most common histological subtype 
found in the background of ACDK in dialysis patients, according for 42-71% of cases28,48. 
Our reevaluation showed that ACDK-RCC, but not papillary RCC, was the major 
histological subtype, accounting for 56.7% tumors in kidneys harbouring ACDK (50% 
patients), while papillary RCC was found only in 5.3%. Nouh et al. also reported a lower 
frequency of papillary RCC in dialysis patients (11%)49. 
The present study clearly showed that the histological spectrum of RCC differed according 
to the duration of dialysis, i.e. conventional clear cell RCC was the predominant subtype in 
patients with shorter duration of dialysis. Especially, within three 3 years, 91% cases were 
clear cell RCC, which is similar to histological spectrum of sporadic RCC. On the other 
hand, ACDK-RCC was the major histological subtype in those on dialysis for ≥ 10 years. 
These findings were identical to the findings reported by Nouh et al.49 in Japanese 
population.  
Generally, the biologic behavior of RCCs in ESRD is reported to be less aggressive than the 
RCCs in sporadic or non-ESRD setting6,50. However, some cases have been reported to 
behave aggressively and metastasize23,49. In the present study, two death from cancer were 
detected. All these two tumors were ACDK-RCC with long term dialysis more than 20 
years, which is in line with other reports23,49.  
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5. Conclusion 
In conclusion, ACDK in patients with ESRD is a potential risk factor for the development of 
RCC. The risk is further increased by a longer duration of dialysis, which might increase the 
possibility of developing more aggressive histological subtypes of RCC with an unfavorable 
prognosis. The spectrum of RCC histological subtypes arising in ESRD is distinct from that 
of sporadic tumors. We believe that MIES RN, which is completed via a single port that 
narrowly permits extraction of the kidney with perinephric fat without CO2 gas insufflation 
and without injury to the peritoneum, is a feasible treatment option for ESRD patients. 
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